abstract：OBJECTIVE:The objectives of the study are to evaluate which clinicopathologic factors influenced overall survival (OS) in endometrial carcinoma and to determine if the surgical effort to assess para-aortic (PA) lymph nodes (LNs) at initial staging surgery impacts OS. METHODS:All patients diagnosed with endometrial can...

journal_title：Gynecologic oncology

authors： Barlin JN,Zhou Q,St Clair CM,Iasonos A,Soslow RA,Alektiar KM,Hensley ML,Leitao MM Jr,Barakat RR,Abu-Rustum NR

更新日期：2013-09-01 00:00:00

abstract：OBJECTIVE:The conditionally replicative adenovirus Ad5/3-Δ24 has a type-3 knob incorporated into the type-5 fiber that facilitates enhanced ovarian cancer infectivity. Preclinical studies have shown that Ad5/3-Δ24 achieves significant oncolysis and anti-tumor activity in ovarian cancer models. The purpose of this study...

journal_title：Gynecologic oncology

authors： Kim KH,Dmitriev IP,Saddekni S,Kashentseva EA,Harris RD,Aurigemma R,Bae S,Singh KP,Siegal GP,Curiel DT,Alvarez RD

更新日期：2013-09-01 00:00:00

abstract：OBJECTIVE:To evaluate the effect of margin status and radiation dose in patients treated with radiation therapy (RT) for vulvar cancer. Clinical outcomes included vulvar recurrence (VR), relapse-free survival (RFS) and overall survival (OS). METHODS:We retrospectively reviewed the records of 300 patients with Stage I-...

journal_title：Gynecologic oncology

authors： Viswanathan AN,Pinto AP,Schultz D,Berkowitz R,Crum CP

更新日期：2013-09-01 00:00:00

abstract：OBJECTIVE:To compare the diagnostic accuracy of dilatation & curettage (D&C) vs. endometrial aspiration biopsy in follow-up evaluation of patients treated with high-dose oral progestin plus levonorgestrel intrauterine system (LNG-IUS) for early-stage endometrial cancer (EC). METHOD:A prospective observational study wa...

journal_title：Gynecologic oncology

authors： Kim MK,Seong SJ,Song T,Kim ML,Yoon BS,Jun HS,Lee GH,Lee YH

更新日期：2013-09-01 00:00:00

abstract：:For the past several years, all women with epithelial ovarian cancer have been treated identically, whether in a clinical trial or off protocol. Over the past decade, we have come to appreciate the magnitude of the heterogeneity of ovarian cancer. The development of the binary grading system for serous carcinoma was a...

journal_title：Gynecologic oncology

authors： Romero I,Sun CC,Wong KK,Bast RC Jr,Gershenson DM

更新日期：2013-09-01 00:00:00

abstract：OBJECTIVES:While most women with ovarian cancer will achieve complete remission after treatment, the majority will relapse within two years, highlighting the need for novel therapies. Cancer stem cells (CSC) have been identified in ovarian cancer and most other carcinomas as a small population of cells that can self-re...

journal_title：Gynecologic oncology

authors： Skubitz AP,Taras EP,Boylan KL,Waldron NN,Oh S,Panoskaltsis-Mortari A,Vallera DA

更新日期：2013-09-01 00:00:00

abstract：BACKGROUND:High tumor dissemination (HTD) is a major risk factor for serious morbidity after primary ovarian cancer (OC) surgery, particularly in medically compromised patients. We performed a pilot study of whether CT findings could predict extent of disease and surgical complexity necessary in advanced OC. METHODS:P...

journal_title：Gynecologic oncology

authors： Glaser G,Torres M,Kim B,Aletti G,Weaver A,Mariani A,Hartmann L,Cliby W

更新日期：2013-08-01 00:00:00

abstract：OBJECTIVE:Many gynecologic oncology (GO) patients in Virginia are low income and their care is supplemented by Disproportionate Share Hospital (DSH) funds. Our objective is to estimate how many new GO patients may lose access to care if the state forgoes Medicaid expansion. METHODS:New patients referred to the GO serv...

journal_title：Gynecologic oncology

authors： Courtney-Brooks M,Pelkofski EB,Engelhard CL,Duska LR

更新日期：2013-08-01 00:00:00

abstract：OBJECTIVE:We evaluated the activity and safety of the combination of topotecan, cisplatin and bevacizumab in patients with recurrent or persistent carcinoma of the cervix. METHODS:Eligible patients had persistent or recurrent cervical cancer not amenable to curative intent treatment. No prior chemotherapy for recurren...

journal_title：Gynecologic oncology

authors： Zighelboim I,Wright JD,Gao F,Case AS,Massad LS,Mutch DG,Powell MA,Thaker PH,Eisenhauer EL,Cohn DE,Valea FA,Alvarez Secord A,Lippmann LT,Dehdashti F,Rader JS

更新日期：2013-07-01 00:00:00

abstract：OBJECTIVES:The efficacy and safety of bevacizumab and docetaxel were evaluated in women who developed recurrent epithelial ovarian, fallopian, or peritoneal cancer within 12 months of platinum-based therapy. METHODS:Patients received docetaxel (40 mg/m(2)) on days 1 and 8 and bevacizumab (15 mg/kg) on day 1 of a 21-da...

journal_title：Gynecologic oncology

authors： Wenham RM,Lapolla J,Lin HY,Apte SM,Lancaster JM,Judson PL,Gonzalez-Bosquet J,Herschberger A,Havrilesky LJ,Secord AA

更新日期：2013-07-01 00:00:00

abstract：OBJECTIVE:Previous studies suggest that differences in molecular features of endometrial cancers between racial groups may contribute to the poorer survival in Blacks. The objective of this investigation was to determine whether gene expression among endometrial cancers is different between Blacks and Whites. METHODS:...

journal_title：Gynecologic oncology

authors： Maxwell GL,Allard J,Gadisetti CV,Litzi T,Casablanca Y,Chandran U,Darcy KM,Levine DA,Berchuck A,Hamilton CA,Conrads TP,Risinger JI

更新日期：2013-07-01 00:00:00

abstract：OBJECTIVE:To assess and characterize the temporal variation in ovarian cancer incidence and mortality by age within countries in the Americas, Europe, Asia, and Oceania. METHODS/MATERIALS:Data from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program in the United States (U.S.) were used...

journal_title：Gynecologic oncology

authors： Lowe KA,Chia VM,Taylor A,O'Malley C,Kelsh M,Mohamed M,Mowat FS,Goff B

更新日期：2013-07-01 00:00:00

abstract：OBJECTIVES:To determine prognostic factors for survival in ovarian cancer patients treated with intraperitoneal (IP) chemotherapy using ancillary data from cooperative group clinical trials. METHODS:Data were collected from 428 patients with stage III ovarian cancer who underwent optimal surgical cytoreduction (<1 cm)...

journal_title：Gynecologic oncology

authors： Landrum LM,Java J,Mathews CA,Lanneau GS Jr,Copeland LJ,Armstrong DK,Walker JL

更新日期：2013-07-01 00:00:00

abstract：BACKGROUND:A phase II trial was performed to evaluate the efficacy and safety of gefitinib in patients with persistent/recurrent endometrial cancer. METHODS:Women with histologically confirmed persistent/recurrent endometrial cancer were treated with 500mg oral gefitinib daily until progression or severe toxicity, wit...

journal_title：Gynecologic oncology

authors： Leslie KK,Sill MW,Fischer E,Darcy KM,Mannel RS,Tewari KS,Hanjani P,Wilken JA,Baron AT,Godwin AK,Schilder RJ,Singh M,Maihle NJ

更新日期：2013-06-01 00:00:00

abstract：:The Patient Protection and Affordable Care Act (ACA) was signed into law by President Barack Obama in 2010. While initial implementation of the law began shortly thereafter, the full implementation will take place over the next few years. With respect to cancer care, the act was intended to make care more accessible, ...

journal_title：Gynecologic oncology

authors： Duska LR,Engelhard CL

更新日期：2013-06-01 00:00:00

abstract：OBJECTIVE:To compare outcomes of patients undergoing continent or incontinent urinary diversion after pelvic exenteration for gynecologic malignancies. METHODS:Data on patients who underwent pelvic exenteration for gynecologic malignancies at The University of Texas MD Anderson Cancer Center between January 1993 and D...

journal_title：Gynecologic oncology

authors： Urh A,Soliman PT,Schmeler KM,Westin S,Frumovitz M,Nick AM,Fellman B,Urbauer DL,Ramirez PT

更新日期：2013-06-01 00:00:00

abstract：OBJECTIVE:Although the epidemiology of typical endometrial carcinomas (grades 1-2 endometrioid or Type I) is well established, less is known regarding higher grade endometrioid or non-endometrioid carcinomas (Type II). Within a large Gynecologic Oncology Group trial (GOG-210), which included central pathology review, w...

journal_title：Gynecologic oncology

authors： Brinton LA,Felix AS,McMeekin DS,Creasman WT,Sherman ME,Mutch D,Cohn DE,Walker JL,Moore RG,Downs LS,Soslow RA,Zaino R

更新日期：2013-05-01 00:00:00

abstract：OBJECTIVE:To prospectively evaluate tumor control, survival, and toxic effects in patients with International Federation of Gynecology and Obstetrics (1988) stage I-IIIA papillary serous carcinoma of the endometrium treated with concurrent chemoradiation and adjuvant chemotherapy. METHODS:Thirty-two patients were enro...

journal_title：Gynecologic oncology

authors： Jhingran A,Ramondetta LM,Bodurka DC,Slomovitz BM,Brown J,Levy LB,Garcia ME,Eifel PJ,Lu KH,Burke TW

更新日期：2013-05-01 00:00:00

abstract：OBJECTIVE:Human leukocyte antigens (HLA) play an important role in presenting virus antigens to immune cells that are responsible for the clearance of virus-infected cells and tumor cells. Herein, we evaluated whether genetic variants of HLA-DP and HLA-DQ are associated with cervical cancer risk. METHODS:We genotyped ...

journal_title：Gynecologic oncology

authors： Jiang J,Li N,Shen Y,Liu J,Liu L,Du J,Lei Y,Wen Y,Yang L,Guo L,Zhang K,Qiang F,Wang S,Hu Z,Dai M,Shen H

更新日期：2013-05-01 00:00:00

abstract：OBJECTIVE:The aim of the study was to examine whether comorbidity is an independent prognostic factor for 3129 women diagnosed with ovarian cancer from 2005 to 2011. As Performance status (PS) might capture the impact of comorbidity we addressed whether comorbidity can be explained by PS or whether comorbidity has an i...

journal_title：Gynecologic oncology

authors： Sperling C,Noer MC,Christensen IJ,Nielsen ML,Lidegaard Ø,Høgdall C

更新日期：2013-04-01 00:00:00

abstract：BACKGROUND:Neuroendocrine carcinomas (NECs) of the cervix comprise only 2% of all cervical cancers. Prospective data is limited and treatment guidelines rely on retrospective reviews and literature from lung NEC. The objective of this study was to report our experience in the management of this rare disease. METHODS:T...

journal_title：Gynecologic oncology

authors： McCann GA,Boutsicaris CE,Preston MM,Backes FJ,Eisenhauer EL,Fowler JM,Cohn DE,Copeland LJ,Salani R,O'Malley DM

更新日期：2013-04-01 00:00:00

abstract：OBJECTIVES:Uterine adenosarcomas (AS) are rare tumors composed of malignant stromal and benign epithelial components. We sought to evaluate the role of primary surgery, adjuvant treatments, and salvage therapies for patients with uterine adenosarcomas. METHODS:We identified all patients diagnosed with AS from 1990 to ...

journal_title：Gynecologic oncology

authors： Tanner EJ,Toussaint T,Leitao MM Jr,Hensley ML,Soslow RA,Gardner GJ,Jewell EL

更新日期：2013-04-01 00:00:00

abstract：OBJECTIVE:Primary debulking surgery (PDS) has historically been the standard treatment for advanced ovarian cancer. Recent data appear to support a paradigm shift toward neoadjuvant chemotherapy with interval debulking surgery (NACT-IDS) for a subset of women with advanced ovarian cancer. It remains unresolved whether ...

journal_title：Gynecologic oncology

authors： Rauh-Hain JA,Nitschmann CC,Worley MJ Jr,Bradford LS,Berkowitz RS,Schorge JO,Campos SM,del Carmen MG,Horowitz NS

更新日期：2013-04-01 00:00:00

abstract：OBJECTIVE:Bladder dysfunction caused by autonomic nerve injury is a well-recognized complication of pelvic surgery. Modified posterior exenteration with or without nerve preservation was performed in patients with primary ovarian, tubal, peritoneal, and endometrial cancer. The aim of this retrospective study was to eva...

journal_title：Gynecologic oncology

authors： Kato K,Tate S,Nishikimi K,Shozu M

更新日期：2013-04-01 00:00:00

abstract：OBJECTIVE:Placental-site trophoblastic tumor (PSTT) is the rarest form of gestational trophoblastic disease (GTD). A risk-adapted treatment approach has been advocated, but controversy exists as to the most important prognostic markers for this disease. Our goal was to determine the prognostic markers for patients with...

journal_title：Gynecologic oncology

authors： Hyman DM,Bakios L,Gualtiere G,Carr C,Grisham RN,Makker V,Sonoda Y,Aghajanian C,Jewell EL

更新日期：2013-04-01 00:00:00

abstract：PURPOSE:To analyze quality of life (QOL) in a randomized, placebo-controlled phase III trial concluding that the addition of concurrent and maintenance bevacizumab (Arm 3) to carboplatin and paclitaxel prolongs progression-free survival in front-line treatment of advanced ovarian cancer compared to chemotherapy alone (...

journal_title：Gynecologic oncology

authors： Monk BJ,Huang HQ,Burger RA,Mannel RS,Homesley HD,Fowler J,Greer BE,Boente M,Liang SX,Wenzel L

更新日期：2013-03-01 00:00:00

abstract：OBJECTIVE:This two-arm longitudinal study was performed within a regional organized cervical-cancer-prevention program in which HPV-DNA test is used in primary screening. The aim was to analyze the diagnostic performances of p16INK4a/Ki-67 dual-test and E6/E7-mRNA test in identifying CIN2+ lesion among HPV-DNA positive...

journal_title：Gynecologic oncology

authors： Zappacosta R,Caraceni D,Ciccocioppo L,Rotondo T,Capanna S,Gatta DM,D'Angelo C,Rosini S

更新日期：2013-03-01 00:00:00

abstract：OBJECTIVES:Few studies have comprehensively tested all ovarian cancer patients for BRCA1 and BRCA2 (BRCA1/2) mutations. We sought to determine if clinically identified mutation carriers differed in clinical characteristics and outcomes from mutation carriers not identified during routine clinical care. METHODS:We incl...

journal_title：Gynecologic oncology

authors： Norquist BM,Pennington KP,Agnew KJ,Harrell MI,Pennil CC,Lee MK,Casadei S,Thornton AM,Garcia RL,Walsh T,Swisher EM

更新日期：2013-03-01 00:00:00

abstract：OBJECTIVES:53BP1, a critical mediator of the DNA damage response, functions by regulating the balance between homologous recombination (HR) and the more error-prone non-homologous endjoining (NHEJ). Deletion of 53BP1 in brca1 (but not brca2) null cells partially restores HR and reverses sensitivity to poly-ADP-ribose p...

journal_title：Gynecologic oncology

authors： Pennington KP,Wickramanayake A,Norquist BM,Pennil CC,Garcia RL,Agnew KJ,Taniguchi T,Welcsh P,Swisher EM

更新日期：2013-03-01 00:00:00

abstract：OBJECTIVES:To evaluate recurrence-free survival (RFS) and overall survival (OS) for patients who underwent robotic-assisted laparoscopic hysterectomy (RALH) for uterine malignancies. METHODS:Medical records from 372 patients with uterine malignancies who underwent RALH from 3/06 to 3/09 at two institutions were review...

journal_title：Gynecologic oncology

authors： Brudie LA,Backes FJ,Ahmad S,Zhu X,Finkler NJ,Bigsby GE 4th,Cohn DE,O'Malley D,Fowler JM,Holloway RW

更新日期：2013-02-01 00:00:00

abstract：OBJECTIVE:To develop a nomogram for predicting the probability of 5year survival after definitive concurrent chemoradiotherapy (CCRT) in locally advanced cervical cancer (LACC). METHODS:Between 1998 and 2008, 209 patients with LACC were treated with definitive CCRT. Multivariate analysis using Cox proportional hazards...

journal_title：Gynecologic oncology

authors： Shim SH,Lee SW,Park JY,Kim YS,Kim DY,Kim JH,Kim YM,Kim YT,Nam JH

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVE:To determine if there is an advantage to combination chemotherapy and radiation for optimally resected stage IIIC endometrial cancer (EC). METHODS:A multicenter retrospective analysis of patients with EC from 1991 to 2008 was conducted. Inclusion criteria were lymph node assessment and optimally resected dis...

journal_title：Gynecologic oncology

authors： Secord AA,Geller MA,Broadwater G,Holloway R,Shuler K,Dao NY,Gehrig PA,O'Malley DM,Finkler N,Havrilesky LJ

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVE:The study aims at identifying novel markers for circulating tumor cells (CTCs) in patients with epithelial ovarian cancer (EOC), and at evaluating their impact on outcome. METHODS:Microarray analysis comparing matched EOC tissues and peripheral blood leucocytes (N=35) was performed to identify novel CTC mark...

journal_title：Gynecologic oncology

authors： Obermayr E,Castillo-Tong DC,Pils D,Speiser P,Braicu I,Van Gorp T,Mahner S,Sehouli J,Vergote I,Zeillinger R

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVE:To evaluate the sensitivity of sentinel node (SN) ultrastaging and to define parameters that may reduce the overall false-negative rate in women with early-stage cervical cancer. METHODS:We analyzed data from a large retrospective multicenter cohort group with FIGO stages IA-IIB cervical cancer in whom at le...

journal_title：Gynecologic oncology

authors： Cibula D,Abu-Rustum NR,Dusek L,Slama J,Zikán M,Zaal A,Sevcik L,Kenter G,Querleu D,Jach R,Bats AS,Dyduch G,Graf P,Klat J,Meijer CJ,Mery E,Verheijen R,Zweemer RP

更新日期：2012-12-01 00:00:00

abstract：BACKGROUND:Although overall cervical cancer incidence rates have decreased in both black and white women in the U.S. since the mid 1950s due to widespread screening, rates continue to be higher among blacks than among whites. However, whether this pattern differs by age is unknown. METHODS:Cervical cancer cases (1975-...

journal_title：Gynecologic oncology

authors： Simard EP,Naishadham D,Saslow D,Jemal A

更新日期：2012-12-01 00:00:00

abstract：OBJECTIVE:The aim of this study was to determine the rate of occult metastasis, including isolated tumor cells, in para-aortic lymph nodes of patients with stage IIIC1 endometrial cancer who underwent pelvic and para-aortic lymphadenectomy. METHODS:A series of 15 patients who had undergone combined pelvic and para-aor...

journal_title：Gynecologic oncology

authors： Todo Y,Suzuki Y,Azuma M,Hatanaka Y,Konno Y,Watari H,Kato H,Matsuno Y,Yamashiro K,Sakuragi N

更新日期：2012-12-01 00:00:00

abstract：:PI3K/AKT/mTOR pathway is a crucial mediator of tumor progression. As the PI3K/Akt pathway is heavily deregulated in breast cancer, the application of mTOR inhibitors in breast cancer patients seems warranted. This is the first systematic review according to PRISMA guidelines to synthesize all available data of mTOR in...

journal_title：Gynecologic oncology

authors： Zagouri F,Sergentanis TN,Chrysikos D,Filipits M,Bartsch R

更新日期：2012-12-01 00:00:00

abstract：OBJECTIVE:To evaluate the clinicopathological features of ovarian Sertoli-Leydig cell tumors (SLCTs) and to explore the reasonable therapy. METHODS:A total of 40 cases of SLCTs were retrospectively reviewed. RESULTS:The incidence of SLCTs was 0.41%, with a median age of 28 years. All tumors were confined to one ovary...

journal_title：Gynecologic oncology

authors： Gui T,Cao D,Shen K,Yang J,Zhang Y,Yu Q,Wan X,Xiang Y,Xiao Y,Guo L

更新日期：2012-11-01 00:00:00

abstract：OBJECTIVE:Epidemiological data indicate that endometriosis increases the risk of epithelial ovarian cancer (EOC), but the mechanism of cancer transition is unknown. Results from genome-wide association studies (GWAS) and transcriptome sequencing have demonstrated that genes located in the 1p36 region are important in b...

journal_title：Gynecologic oncology

authors： Falconer H,Sundqvist J,Xu H,Vodolazkaia A,Fassbender A,Kyama C,Bokor A,D'Hooghe TM

更新日期：2012-11-01 00:00:00

abstract：:Surgical treatment including total abdominal hysterectomy+bilateral salpingo oopherectomy (TAH+BSO) with pelvic and para-aortic lymphadenectomy may not be sufficient to treat cases with advanced endometrial adenocarcinoma (EAC), and in these cases, adjuvant treatments including radiotherapy and/or chemotherapy, are em...

journal_title：Gynecologic oncology

authors： Thangaraju S,Subramani E,Chakravarty B,Chaudhury K

更新日期：2012-11-01 00:00:00